Valeant

Valeant Pharmaceuticals Under Fresh Scrutiny Over Drug Pricing

Valeant Pharmaceuticals disclosed late Wednesday that it was subpoenaed by U.S. prosecutors seeking information on its pricing programs.

In early trading on Thursday, Valeant’s U.S.-listed shares were down 9% at $156.53.


Valeant under fire for increasing drug prices
Valeant Pharmaceuticals has received subpoenas from U.S. prosecutors seeking information on drug-pricing decisions. In a statement on Wednesday night, the Canada-based . . .

SORRY!

This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here

If you are subscribed and having an account error please clear cache and then cookies if that does not work email support@valuewalk.com and we will get back to you as quick as humanly possible


Saved Articles
X
TextTExtLInkTextTExtLInk

Subscribe to our mailing list

* indicates required

Opt out of occasional 3rd party offers


0